Page last updated: 2024-11-08

org 31806

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Org 31806: structure given in first source; progestational hormone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164147
SCHEMBL ID7632063
MeSH IDM0205003

Synonyms (9)

Synonym
org 31806
123916-70-1
spiro(estra-4,9-diene-17,2'(3'h)-furan)-3-one, 11-(4-(dimethylamino)phenyl)-4',5'-dihydro-7-methyl-, (7beta,11beta,17beta)-
org-31806
11-(4-dimethylaminophenyl)-7-methyl-4',5'-dihydro(estra-4,9-diene-17,2'-(3h)-furan)-3-one
SCHEMBL7632063
11-[4-(dimethylamino)phenyl]-7,13-dimethyl-1,6,7,8,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-oxolan]-3(2h)-one
DTXSID20924638
(7s,8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-7,13-dimethylspiro[1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17,2'-oxolane]-3-one

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated."( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997
)
0.55
"The pregnancy termination potency of varying doses of mifepristone, onapristone, and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated in adult rats."( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat.
Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]